Form 4: Theravance Biopharma SVP Sells Shares for Tax Obligations

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, disposed of 9,060 ordinary shares to cover tax obligations related to vested restricted stock units.

Summary

• Rhonda Farnum, SVP, Communications & Medical Affairs at Theravance Biopharma, Inc. (TBPH), reported a transaction on November 20, 2025.
• 9,060 ordinary shares were disposed of at a price of $17.9 per share.
• The transaction code 'F' indicates that these shares were withheld by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• This was not an open market transaction.
• Following this transaction, Rhonda Farnum directly beneficially owns 308,762 ordinary shares.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction for tax purposes and does not reflect a discretionary sale or a change in company fundamentals.

Related Party Transactions

• Shares were withheld by the issuer (Theravance Biopharma, Inc.) to satisfy tax obligations, which is a transaction between the reporting person and the company.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary transaction for tax purposes, not an open market sale indicating a change in sentiment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by an insider to cover tax obligations upon the vesting of restricted stock units. It does not indicate any change in the company's fundamentals, strategic direction, or the insider's confidence in the company. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

Theravance Biopharma, TBPH, Form 4, insider transaction, share disposition, tax withholding, restricted stock units, RSU, Rhonda Farnum